Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.

Li R, Ou J, Li L, Yang Y, Zhao J, Wu R.

Front Pharmacol. 2018 Apr 16;9:379. doi: 10.3389/fphar.2018.00379. eCollection 2018.

2.

TCF7L2 polymorphisms and the risk of schizophrenia in the Chinese Han population.

Liu L, Li J, Yan M, Li J, Chen J, Zhang Y, Zhu X, Wang L, Kang L, Yuan D, Jin T.

Oncotarget. 2017 Apr 25;8(17):28614-28620. doi: 10.18632/oncotarget.15603.

3.

Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function.

Kennedy AJ, Rahn EJ, Paulukaitis BS, Savell KE, Kordasiewicz HB, Wang J, Lewis JW, Posey J, Strange SK, Guzman-Karlsson MC, Phillips SE, Decker K, Motley ST, Swayze EE, Ecker DJ, Michael TP, Day JJ, Sweatt JD.

Cell Rep. 2016 Sep 6;16(10):2666-2685. doi: 10.1016/j.celrep.2016.08.004. Epub 2016 Aug 25.

5.

Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample.

Alkelai A, Greenbaum L, Lupoli S, Kohn Y, Sarner-Kanyas K, Ben-Asher E, Lancet D, Macciardi F, Lerer B.

PLoS One. 2012;7(1):e29228. doi: 10.1371/journal.pone.0029228. Epub 2012 Jan 11.

6.

Modulation ofTcf7l2 expression alters behavior in mice.

Savic D, Distler MG, Sokoloff G, Shanahan NA, Dulawa SC, Palmer AA, Nobrega MA.

PLoS One. 2011;6(10):e26897. doi: 10.1371/journal.pone.0026897. Epub 2011 Oct 27.

7.

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, Jakobsen KD, Rasmussen HB, Tosato S, Rietschel M, Frank J, Owen M, Bonetto C, Suvisaari J, Thygesen JH, Pétursson H, Lönnqvist J, Sigurdsson E, Giegling I, Craddock N, O'Donovan MC, Ruggeri M, Cichon S, Ophoff RA, Pietiläinen O, Peltonen L, Nöthen MM, Rujescu D, St Clair D, Collier DA, Andreassen OA, Werge T.

Biol Psychiatry. 2011 Jul 1;70(1):59-63. doi: 10.1016/j.biopsych.2011.01.031. Epub 2011 Mar 16.

PMID:
21414605
8.

Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder.

Irvin MR, Wiener HW, Perry RP, Savage RM, Go RC.

Schizophr Res. 2009 Oct;114(1-3):50-6. doi: 10.1016/j.schres.2009.07.008. Epub 2009 Jul 29.

9.

Anticipation and CAG*CTG repeat expansion in schizophrenia and bipolar affective disorder.

Fortune MT, Kennedy JL, Vincent JB.

Curr Psychiatry Rep. 2003 Jun;5(2):145-54. Review.

PMID:
12685994
10.

Repeat sizes at CAG/CTG loci CTG18.1, ERDA1 and TGC13-7a in schizophrenia.

Bowen T, Guy CA, Cardno AG, Vincent JB, Kennedy JL, Jones LA, Gray M, Sanders RD, McCarthy G, Murphy KC, Owen MJ, O'Donovan MC.

Psychiatr Genet. 2000 Mar;10(1):33-7.

PMID:
10909126
11.

Allelic distribution of CTG18.1 in Caucasian populations: association studies in bipolar disorder, schizophrenia, and ataxia.

McInnis MG, Swift-Scanlanl T, Mahoney AT, Vincent J, Verheyen G, Lan TH, Oruc L, Riess O, Van Broeckhoven C, Chen H, Kennedy JL, MacKinnon DF, Margolis RL, Simpson SG, McMahon FJ, Gershon E, Nurnberger J, Reich T, DePaulo JR, Ross CA.

Mol Psychiatry. 2000 Jul;5(4):439-42.

PMID:
10889556

Supplemental Content

Loading ...
Support Center